Mirum Pharmaceuticals is trading 4.03% down at $94.84, with no fresh company-specific announcement or clearly reported September 18, 2026 catalyst identified.
- Recent coverage continues to discuss the FDA-requested Phase 3 study for volixibat in primary sclerosing cholangitis and delayed filing timing.
- Those developments were previously disclosed rather than new today.
- The decline also diverges from the biotechnology sector’s advance.